Summary
65.63 1.37(2.12%)11/22/2024
Astrazeneca plc (AZN)
AZN reported last earnings on 2024-11-12 after the market. An EPS of $1.04 was observed compared to an estimated EPS of $1.01, resulting in a surprise value of $0.03. A revenue of $13,565 million was observed compared to an estimated revenue of $13,088 million, resulting in a surprise value of $477 Million.
Astrazeneca plc (AZN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.12 | 3.79 | -15.17 | -23.54 | -16.71 | 3.17 | 51.14 | 3,607.63 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Earnings
Fundamental Ratings
| Category | Rating |
| Main Rating | B |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
| Trading Data | ||
| Close | 65.63 | |
| Open | 65.70 | |
| High | 66.46 | |
| Low | 65.57 | |
| Volume | 5,178,561 | |
| Change | 1.37 | |
| Change % | 2.12 | |
| Avg Volume (20 Days) | 7,948,598 | |
| Volume/Avg Volume (20 Days) Ratio | 0.65 | |
| 52 Week Range | 60.47 - 87.67 | |
| Price vs 52 Week High | -25.15% | |
| Price vs 52 Week Low | 8.52% | |
| Range | -0.11 | |
| Gap Up/Down | 1.36 | |
Fundamentals | ||
| Market Capitalization (Mln) | 242,403 | |
| EBIDTA | 15,802,999,808 | |
| PE Ratio | 38.2079 | |
| PEG Ratio | 0.8861 | |
| WallStreet Target Price | 82.74 | |
| Book Value | 24.1740 | |
| Earnings Per Share | 2.0200 | |
| EPS Estimate Current Quarter | 1.2200 | |
| EPS Estimate Next Quarter | 1.3200 | |
| EPS Estimate Current Year | 4.0600 | |
| EPS Estimate Next Year | 5.7200 | |
| Diluted EPS (TTM) | 2.0200 | |
| Revenues | ||
| Profit Marging | 0.1330 | |
| Operating Marging (TTM) | 0.2611 | |
| Return on asset (TTM) | 0.0704 | |
| Return on equity (TTM) | 0.1729 | |
| Revenue TTM | 47,610,998,784 | |
| Revenue per share TTM | 2.5512 | |
| Quarterly Revenue Growth (YOY) | 0.1650 | |
| Quarterly Earnings Growth (YOY) | 0.2070 | |
| Gross Profit (TTM) | 35,732,000,000 | |
| Dividends | ||
| Dividend Share | 2.9000 | |
| Dividend Yield | 0.0188 | |
| Valuations | ||
| Trailing PE | 38.2079 | |
| Forward PE | 16.3132 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.4598 | |
| Revenue Enterprise Value | 5.1971 | |
| EBITDA Enterprise Value | 17.7384 | |
| Shares | ||
| Shares Outstanding | 3,100,470,016 | |
| Shares Float | 1,543,222,230 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.01 | |
| Institutions (%) | 16.86 | |
11/22 12:15 EST - accesswire.com
Lost Money on AstraZeneca PLC (AZN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
Lost Money on AstraZeneca PLC (AZN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
11/22 11:00 EST - accesswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
11/22 11:00 EST - accesswire.com
An Investigation Has Commenced on Behalf of AstraZeneca PLC Shareholders. Contact Levi & Korsinsky to Discuss Your AZN Losses
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
An Investigation Has Commenced on Behalf of AstraZeneca PLC Shareholders. Contact Levi & Korsinsky to Discuss Your AZN Losses
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
11/21 04:57 EST - fool.com
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
11/20 16:15 EST - accesswire.com
AstraZeneca PLC (AZN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
AstraZeneca PLC (AZN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
11/20 15:45 EST - accesswire.com
AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - AZN
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - AZN
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
11/20 07:30 EST - accesswire.com
Levi & Korsinsky Reminds Shareholders of an Investigation into AstraZeneca PLC (AZN) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
Levi & Korsinsky Reminds Shareholders of an Investigation into AstraZeneca PLC (AZN) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
11/20 07:30 EST - businesswire.com
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This...
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This...
11/20 03:06 EST - proactiveinvestors.co.uk
AstraZeneca hits out at NICE block to breast cancer drug
AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo said they are 'disappointed and disagree' with a decision by the UK medicines regulator not to give the green light to a breast cancer drug they jointly developed. Talks to approve Enhertu for NHS used collapsed over pricing and despite the intervention...
AstraZeneca hits out at NICE block to breast cancer drug
AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo said they are 'disappointed and disagree' with a decision by the UK medicines regulator not to give the green light to a breast cancer drug they jointly developed. Talks to approve Enhertu for NHS used collapsed over pricing and despite the intervention...
11/19 09:26 EST - zacks.com
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
11/19 04:40 EST - proactiveinvestors.co.uk
Goldman: Buy British for better returns in 2025
In its latest outlook for 2025, Goldman Sachs is urging investors to “buy British” as undervalued UK stocks offer an attractive opportunity in Europe's otherwise tepid equity market. The bank highlights that UK shares, particularly those with a domestic focus, are trading at a discount compared...
Goldman: Buy British for better returns in 2025
In its latest outlook for 2025, Goldman Sachs is urging investors to “buy British” as undervalued UK stocks offer an attractive opportunity in Europe's otherwise tepid equity market. The bank highlights that UK shares, particularly those with a domestic focus, are trading at a discount compared...
11/18 22:15 EST - accesswire.com
AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors, Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors, Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that...
11/18 16:01 EST - prnewswire.com
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif. , Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer...
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif. , Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer...
11/18 10:45 EST - zacks.com
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
11/18 09:00 EST - prnewswire.com
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea , Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics,...
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea , Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics,...